Jessie Gu

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

Jessie Gu, Adele Noè, Priya Chandra et al. · The Journal of Clinical Pharmacology · 2009 · 502 citations

Medicine, Pharmacokinetics, Pharmacology +17

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Konstantin Dobrenkov, Irina Ostrovnaya, Jessie Gu et al. · Pediatric Blood & Cancer · 2016 · 147 citations · Full text

Medicine, Oncology, Pathology +17

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

Yasushi Goto, Wu‐Chou Su, Benjamin Levy et al. · Journal of Clinical Oncology · 2023 · 52 citations

Pharmacy, Oncology, Pharmacology +16

A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2013 · 49 citations

Medicine, Oncology, Pharmacology +9

The Potential of Genes and Other Markers to Inform about Risk

Margaret S. Pepe, Jessie Gu, Daryl E. Morris · Cancer Epidemiology Biomarkers & Prevention · 2010 · 44 citations · Full text

Life Sciences, Biostatistics, Genetics +17